ENLV — Enlivex Therapeutics Ltd.
$0.1734-12.95%
Last close: · regular session
After-hours $0.1800 +3.81% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ENLV in the TickerWise workspace.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ Capital Market
- Employees: 71
- Website: https://www.enlivex.com
Latest SEC filings for ENLV
Latest ENLV news
- Enlivex announces 1-for-16 reverse stock split Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.